Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BB 1701

Next Previous
Drug Profile

BB 1701

Alternative Names: BB-1701

Latest Information Update: 22 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bliss Biopharmaceutical
  • Developer Bliss Biopharmaceutical; Eisai Co Ltd
  • Class 2 ring heterocyclic compounds; Antibodies; Antineoplastics; Cyclic ethers; Drug conjugates; Furans; Immunoconjugates; Ketones; Macrocyclic compounds; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Cadherin modulators; Receptor protein-tyrosine kinase modulators; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II HER2 positive breast cancer; Non-small cell lung cancer
  • Phase I/II Solid tumours

Most Recent Events

  • 13 Sep 2024 Efficacy and adverse events data from a phase II trial in Non-small cell lung cancer presented at the 49th European Society for Medical Oncology Congress (ESMO-2024)
  • 20 Feb 2024 Phase-II clinical trials in HER2-positive-breast-cancer (Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater) in Japan (IV), after February 2024 (NCT06188559)
  • 20 Feb 2024 Phase-II clinical trials in HER2-positive-breast-cancer (Metastatic disease, Second-line therapy or greater, Inoperable/Unresectable) in USA (IV) (NCT06188559)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top